420
Participants
Start Date
July 31, 2024
Primary Completion Date
December 31, 2027
Study Completion Date
June 30, 2029
Anlotinib hydrochloride capsule + TQB2450 injection
"Anlotinib hydrochloride capsule is a multi-target tyrosine kinase inhibitor, which targets VEGFR (VEGFR-1, VEGFR-2 and VEGFR-3), PDGFR, FGFR and c-Kit, etc. It can inhibit tumor progression by inhibiting angiogenesis and tumor growth at the same time.~TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1) that prevents the binding of PD-L1 to the PD-1 and B7.1 receptors on the T-cell surface, allowing T-cell reactivation and thus enhancing the immune response."
Chemotherapy drug
Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs (including Paclitaxel, Albumin, Doxorubicin and Doxorubicin hydrochloride) for treatment.
Shanxi Bethune Hospital, Taiyuan
Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing
Beijing Chaoyang Hospital, Capital Medical University, Beijing
Liaoning Cancer Hospital, Shenyang
Shengjing Hospital Of China Medical University, Shenyang
Changchun Tumor Hospital, Changchun
The first hospital of Jilin University, Changchun
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Shanghai Tenth People's Hospital, Shanghai
Obstetrics & Gynecology Hospital of Fudan University, Shanghai
Anhui Provincial Hospital, Hefei
Shandong Cancer Hospital, Jinan
Binzhou Medical University Hospital, Binzhou
Binzhou People's Hospital, Binzhou
Weifang People's Hospital, Weifang
Yidu Central Hospital Of Weifang, Weifang
Yantai Yuhuangding Hospital, Yantai
Affiliated Hospital of Jining Medical University, Jining
Linyi Cancer Hospital, Linyi
Tengzhou Central People's Hospital, Zaozhuang
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Tianjin Central Hospital of Gynecology Obstetrics, Tianjin
Maternal Health School of Medicine Zhejiang University, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
The Affiliated People's Hospital of Ningbo University, Ningbo
Fujian Cancer Hospital, Fuzhou
Chongqing University Cancer Hospital, Chongqing
The Southwest Hospital of Amu, Chongqing
Chongqing University Three Gorges Hospital, Chongqing
The Second Affiliated Hospital of Chongqing Medical University, Chongqing
Hunan Cancer Hospital, Changsha
The Central Hospital Of Shaoyang, Shaoyang
Hubei Cancer Hospital, Wuhan
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Nanyang first People's Hospital National Third Class A Hospital, Nanyang
Sun Yat-sen Memorial Hospital, Guangzhou
The First Affiliated Hospital of Jinan University, Guangzhou
Meizhou People's Hospital, Meizhou
Huizhou Central People's Hospital, Huizhou
Jiangmen Central Hospital, Jiangmen
Guangxi Medical University Cancer Hospital, Nanning
Guigang City People's Hospital, Guigang
Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin
Liuzhou People's Hospital, Liuzhou
Liuzhou Municipal Liutie Central Hospital, Liuzhou
Hainan Ceneral Hospital, Haikou
The Affiliated Hospital of Southwest Medical University, Chongqing
Yunnan Cancer Hospital, Kunming
The Second Affiliated Hospital of Air Force Medical University, Xi'an
The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an
Shaanxi Provincial People's Hospital, Xi'an
First Hospital of Lanzhou University, Lanzhou
Gansu Provincial Cancer Hospital, Lanzhou
General Hospital Of Ningxia Medical University, Yinchuan
Qinghai Red Cross Hospital, Xining
Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi
Tangshan People's Hospital, Tangshan
Inner Mongolia Autonomous Region People's Hospital, Hohhot
Shanxi Cancer hospital, Taiyuan
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY